One study noted that a higher expression of ERAP2 in the immunoreactive tumor microenvironment of Squamous-cell lung cancer (SqCLC) patients is correlated with high levels of immune markers and cells that include PD-L1, CD47, CD8+ TIL, CD68+ macrophages, and NK cells, which are all positive indicators for immunotherapy [87]. This evidence concerns the gene ERAP2 and squamous cell lung carcinoma.